Symbio, a US contract research organisation (CRO) based in Port Jefferson, New York, has rounded out its portfolio of services by opening a Phase I clinical unit in Michigan City, Indiana.
The 62-bed facility has been set up in Saint Anthony Memorial Hospital, where an entire flo
or is doted to Phase I clinical trials. With downtown Chicago only 45 minutes away, there is easy access to diverse populations of healthy participants, including eight local colleges/universities and technical schools, Symbio pointed out.
The CRO’s activities already ranged from clinical t
rial management to biometrics, strategic consulting, product development and topical formulation development. With the addition of the Phase I unit, Symbio “now has the ability to provide development from Phase I through Phase IV”, it noted.
Established in 2002, Symbio has particular expertise in working with the generic drug industry. The CRO’s Phase I clinical team “is set up to prepare and execute clinical plans to support FDA [Food and Drug Administration] approval of generic products”, it said.
Commenting recently on Kendle’s acquisition of DecisionLine Clinical Research Corporation, a CRO based in Toronto, Canada and specialising in Phase I studies, president Simon Higginbotham noted that Phase I growth was expected to outpace the broader outsourcing market for clinical research at around 15% per annum.
